NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free cccc Stock Alerts $5.71 +0.03 (+0.53%) (As of 10:40 AM ET) Add Compare Share Share Today's Range$5.61▼$5.7550-Day Range$5.68▼$10.7652-Week Range$1.06▼$11.88Volume135,102 shsAverage Volume3.19 million shsMarket Capitalization$392.91 millionP/E RatioN/ADividend YieldN/APrice Target$10.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media C4 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside78.6% Upside$10.11 Price TargetShort InterestBearish14.74% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.56) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.94 out of 5 starsMedical Sector807th out of 918 stocksBiological Products, Except Diagnostic Industry141st out of 155 stocks 3.2 Analyst's Opinion Consensus RatingC4 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about C4 Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.74% of the outstanding shares of C4 Therapeutics have been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 6.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CCCC. Previous Next 1.9 News and Social Media Coverage News SentimentC4 Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 18 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.97% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about C4 Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about C4 Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWarren Buffett's "mystery stock"WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some About C4 Therapeutics Stock (NASDAQ:CCCC)C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More CCCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CCCC Stock News HeadlinesMay 18 at 4:50 AM | americanbankingnews.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 6.1% in AprilMay 17 at 3:31 PM | finance.yahoo.comC4 Therapeutics, Inc. (CCCC)May 13, 2024 | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) Price Target Raised to $8.00 at Wells Fargo & CompanyMay 13, 2024 | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) Price Target Raised to $14.00 at Stifel NicolausMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)May 13, 2024 | americanbankingnews.comC4 Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.42) Per Share, Brookline Capital Management Forecasts (NASDAQ:CCCC)May 12, 2024 | americanbankingnews.comBrookline Capital Management Weighs in on C4 Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:CCCC)May 10, 2024 | finance.yahoo.comC4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic CollaborationsMay 9, 2024 | markets.businessinsider.comC4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable FinancialsMay 9, 2024 | markets.businessinsider.comKey Takeaways From C4 Therapeutics Analyst RatingsMay 8, 2024 | investorplace.comCCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comC4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 30, 2024 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 29, 2024 | globenewswire.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | seekingalpha.comArvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win SituationApril 9, 2024 | globenewswire.comC4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumApril 8, 2024 | msn.comC4 Dips on Release of DataApril 8, 2024 | finance.yahoo.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024April 8, 2024 | globenewswire.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024March 28, 2024 | finance.yahoo.comHere’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)March 16, 2024 | finance.yahoo.comCCCC Mar 2024 17.000 callMarch 16, 2024 | finance.yahoo.comCCCC Mar 2024 10.000 putMarch 9, 2024 | nasdaq.comGuru Fundamental Report for CCCCMarch 5, 2024 | globenewswire.comC4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024March 4, 2024 | globenewswire.comC4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsSee More Headlines Company Calendar Last Earnings2/22/2024Today5/20/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CCCC CUSIPN/A CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Stock Price Target$10.11 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+78.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,490,000.00 Net Margins-629.24% Pretax Margin-622.85% Return on Equity-52.85% Return on Assets-34.01% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio5.08 Sales & Book Value Annual Sales$20.76 million Price / Sales18.83 Cash FlowN/A Price / Cash FlowN/A Book Value$3.75 per share Price / Book1.51Miscellaneous Outstanding Shares68,810,000Free Float63,322,000Market Cap$390.84 million OptionableOptionable Beta3.22 Key ExecutivesMr. Andrew J. Hirsch M.B.A. (Age 53)CEO, President & Director Comp: $971kDr. Kenneth C. Anderson M.D. (Age 73)Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board Comp: $39.03kDr. Stewart Fisher (Age 57)Chief Scientific Officer Comp: $657.34kMr. Scott N. Boyle M.B.A. (Age 46)Ph.D., Chief Business Officer Comp: $672.78kDr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Kendra AdamsChief Financial OfficerMr. Mark Mossler (Age 51)Chief Accounting Officer Ms. Jolie M. Siegel J.D. (Age 47)Chief Legal Officer & Corporate Secretary Comp: $610.4kMs. Kelly A. Schick (Age 44)Chief People Officer Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business DevelopmentMore ExecutivesKey CompetitorsReplimune GroupNASDAQ:REPLTScan TherapeuticsNASDAQ:TCRXOcugenNASDAQ:OCGNLexeo TherapeuticsNASDAQ:LXEOSolid BiosciencesNASDAQ:SLDBView All CompetitorsInstitutional OwnershipWalleye Trading LLCBought 2,200 shares on 5/17/2024Ownership: 0.000%Bain Capital Life Sciences Investors LLCSold 500,000 shares on 5/16/2024Ownership: 1.660%Caxton Associates LPBought 21,002 shares on 5/16/2024Ownership: 0.031%Price T Rowe Associates Inc. MDSold 443,003 shares on 5/15/2024Ownership: 3.074%Bellevue Group AGSold 4,400 shares on 5/15/2024Ownership: 0.084%View All Institutional Transactions CCCC Stock Analysis - Frequently Asked Questions Should I buy or sell C4 Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CCCC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCCC, but not buy additional shares or sell existing shares. View CCCC analyst ratings or view top-rated stocks. What is C4 Therapeutics' stock price target for 2024? 7 Wall Street analysts have issued 12 month target prices for C4 Therapeutics' shares. Their CCCC share price targets range from $2.00 to $20.00. On average, they anticipate the company's stock price to reach $10.11 in the next year. This suggests a possible upside of 78.6% from the stock's current price. View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts. How have CCCC shares performed in 2024? C4 Therapeutics' stock was trading at $5.65 at the start of the year. Since then, CCCC stock has increased by 0.2% and is now trading at $5.66. View the best growth stocks for 2024 here. When is C4 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CCCC earnings forecast. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its earnings results on Thursday, February, 22nd. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.01. The company earned $3.26 million during the quarter, compared to analyst estimates of $5.23 million. C4 Therapeutics had a negative net margin of 629.24% and a negative trailing twelve-month return on equity of 52.85%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an IPO on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? C4 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (6.31%), Vanguard Group Inc. (4.24%), Price T Rowe Associates Inc. MD (3.07%), Bain Capital Life Sciences Investors LLC (1.66%), Bellevue Group AG (0.08%) and Susquehanna Fundamental Investments LLC (0.07%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Stewart Fisher and Utpal Koppikar. View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CCCC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold4 Cryptos BETTER than BitcoinTrue Market InsidersDoes this make you sick?Allegiance GoldBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist My Default Watchlist Adding C4 Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.